Company Overview and News

 
Tata Sponge Iron Limited - Dividend

2018-04-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - AGM/Book Closure

2018-04-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - Financial Result Updates

2018-04-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-04-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - Outcome of Board Meeting

2018-04-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Closing Bell: Sensex ends rangebound session higher; hotels, jewellery, realty stocks rally

2018-04-17 moneycontrol
3:30 pm Market Closing: Benchmark indices managed to end near day's high after volatility throughout the session.

 
Market Live: Nifty holds 10,500 amid consolidation; corporate earnings eyed

2018-04-17 moneycontrol
1:58 pm Car Price Hike: Toyota Kirloskar Motor (TKM) is planning to increase vehicle prices from next month in order to partially offset rise in input costs.

 
Market Live: Sensex, Nifty trade lower; all sectoral indices in red except FMCG

2018-04-17 moneycontrol
12:42 pm Market Update: The market is trading mildly lower amid consolidation, after rising in previous 8 consecutive sessions, as investors look for more corporate earnings due over next one and half months.

 
Market Live: Sensex, Nifty mildly higher amid consolidation; metals, PSU banks shine

2018-04-17 moneycontrol
11:01 am Market Check: Benchmark indices traded with mild gains amid consolidation as investors after digesting normal monsoon forecast look for more corporate earnings.

 
Market Live: Sensex, Nifty erase opening gains as investors digest normal monsoon forecast

2018-04-17 moneycontrol
9:42 am Rupee Trade: The rupee fell 4 paise to 65.53 against the dollar at the interbank forex market.

 
Crisil, Tata Sponge Iron results on Tuesday

2018-04-16 thehindubusinessline
Tuesday will see companies such as Crisil, Gujarat Hotels, International Travel House, Muthoot Finance, Orchid Chemicals and Pharmaceuticals, Schaeffler India and Tata Sponge Iron declaring their results. For Crisil and Schaeffler India, it would be the first quarter results, as they follow calendar year as financial year. Orchid Pharma, which is under insolvency process, will declare December 2017 quarter results.

 
Tata Sponge Iron Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - Updates

2018-03-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Tata Sponge Iron Limited - Trading Window

2018-03-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...